IL6R and rheumatoid arthritis: To corroborate the results we obtained using siRNAs with a more clinically relevant agent, we used tocilizumab (TCZ), an IL-6Rα-targeted monoclonal antibody that is FDA approved for the treatment of rheumatoid arthritis and chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome.